Skip to main content

R&D Surge Widens Illumina s Q4 Net Loss; Revenue Inches Ahead

NEW YORK, Feb. 1 - Illumina on Friday said that a significant increase in R&D spending caused it to post widened net losses in the fourth quarter of 2001.


Losses in the period ended Dec. 31 were $8.2 million, or $0.27 per share, compared with $4.6 million, or $0.16 per share in the year-ago quarter, the company said.


Although revenue in the period increased to $761,000 from $485,000 year over year, R&D spending ballooned to $6.1 million from $3.8 million one year ago.


Illumina, based in San Diego, said it had roughly $94 million in the bank at the end of 2001.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.